Statera Biopharma, Inc. (STAB)
- Previous Close
0.0007 - Open
0.0007 - Bid --
- Ask --
- Day's Range
0.0007 - 0.0007 - 52 Week Range
0.0001 - 0.0380 - Volume
5,384 - Avg. Volume
7,262 - Market Cap (intraday)
49,991 - Beta (5Y Monthly) 278.86
- PE Ratio (TTM)
-- - EPS (TTM)
-2.3600 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. Statera Biopharma, Inc. is based in Fort Collins, Colorado.
www.staterabiopharma.comRecent News: STAB
Performance Overview: STAB
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: STAB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: STAB
Valuation Measures
Market Cap
49.99k
Enterprise Value
6.95M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-23.85%
Return on Equity (ttm)
-286.94%
Revenue (ttm)
3.69M
Net Income Avi to Common (ttm)
-91.83M
Diluted EPS (ttm)
-2.3600
Balance Sheet and Cash Flow
Total Cash (mrq)
506.1k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
340.1k
Research Analysis: STAB
Company Insights: STAB
STAB does not have Company Insights